# Haihe Biopharma

Source: https://onco.cc/companies/haihe-biopharma/  
OnCo record `haihe-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Haihe Biopharma is a China-based biotechnology company running 4 late-stage cancer trials of HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma and sarcomas.

## Summary

Haihe Biopharma, based in Shanghai, China, is a biotechnology company. Haihe Biopharma (Shanghai Haihe Pharmaceuticals) is a China-based biopharmaceutical company focused on the discovery, development, production and commercialisation of innovative drugs, including several oncology candidates. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma, sarcomas, peripheral T-cell lymphomas and hodgkin lymphoma. The largest, NCT04390737 (Evaluate the Safety and Clinical Activity of HH2853), plans to enrol 254 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Haihe Biopharma Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.haihepharma.com

## Sources

- Official website: https://www.haihepharma.com
- ClinicalTrials.gov: trials led by Haihe Biopharma: https://clinicaltrials.gov/search?lead=Haihe%20Biopharma%20Co.%2C%20Ltd.

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [CYH33](https://onco.cc/drugs/cyh33/), [Glumetinib](https://onco.cc/drugs/glumetinib/)
- trials: [A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma](https://onco.cc/trials/nct05043922/), [Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04270591/), [Evaluate the Safety and Clinical Activity of HH2853](https://onco.cc/trials/nct04390737/), [Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma](https://onco.cc/trials/nct06909877/)

---
JSON: https://onco.cc/api/v1/entities/haihe-biopharma.json